Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-90009530 · 1 trial · 1 indication
The safety and tolerability will be measured by recording the occurence and severity of all adverse events or dose limiting toxicities that occur according to Common Terminology Criteria for Adverse Events (CTCAE) criteria version 5.0
Employ a Bayesian optimal interval (BOIN) design and determine the RP2D with review of the number of dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| JNJ-90009530 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ-90009530 | DRUG | JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20 |
Key Inclusion Criteria * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * All participants must have relapsed or refractory disease for each histologic subtype * Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Part...
JNJ-90009530 is an investigational small molecule being studied for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is intended for patients whose disease has not responded to or has returned after prior therapy.
JNJ-90009530 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
JNJ-90009530 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities such as the FDA. The ongoing Phase 1 trial is actively enrolling participants, though recruitment is currently not active, and the study is designed to assess the drug's safety, tolerability, and preliminary efficacy.
JNJ-90009530 is being evaluated in a single Phase 1 clinical trial with the identifier NCT05784441. This study is titled 'A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)' and is being conducted in the United States, Australia, Israel, and the United Kingdom. The trial is currently active but not recruiting participants.
No alternative names for JNJ-90009530 have been disclosed. The drug is identified solely by its development code JNJ-90009530 in clinical trial registries and scientific literature. It is a distinct investigational compound being developed by Johnson & Johnson for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma.